Defining and refining 5-HT receptor targets for migraine

Affiliations

Comment

Andrew Charles. Lancet Neurol. 2012 May.

. 2012 May;11(5):383-4.

doi: 10.1016/S1474-4422(12)70062-5. Epub 2012 Mar 28.

¹ Headache Research and Treatment Program, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA. acharles@ucla.edu

No abstract available

Comment on

Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study.
Färkkilä M, Diener HC, Géraud G, Láinez M, Schoenen J, Harner N, Pilgrim A, Reuter U; COL MIG-202 study group. Färkkilä M, et al. Lancet Neurol. 2012 May;11(5):405-13. doi: 10.1016/S1474-4422(12)70047-9. Epub 2012 Mar 28. Lancet Neurol. 2012. PMID: 22459549 Clinical Trial.